908 Devices Inc. (MASS)

$5.79

-0.28

(-4.61%)▲

Market is closed - opens 7 PM, 16 Apr 2024

Insights on 908 Devices Inc.

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 9.48M → 14.35M (in $), with an average increase of 12.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -7.09M → -7.42M (in $), with an average decrease of 4.7% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 31.5% return, outperforming this stock by 58.6%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 66.4% return, outperforming this stock by 154.8%

Performance

  • $5.70
    $6.06
    $5.79
    downward going graph

    1.55%

    Downside

    Day's Volatility :5.94%

    Upside

    4.46%

    downward going graph
  • $4.85
    $12.51
    $5.79
    downward going graph

    16.23%

    Downside

    52 Weeks Volatility :61.23%

    Upside

    53.72%

    downward going graph

Returns

Period908 Devices Inc.Sector (Technology)Index (Russel 2000)
3 Months
-21.78%
6.6%
0.0%
6 Months
2.19%
20.7%
0.0%
1 Year
-29.91%
38.2%
-0.7%
3 Years
-88.48%
43.3%
-21.8%

Highlights

Market Capitalization
196.5M
Book Value
$5.09
Earnings Per Share (EPS)
-1.13
Wall Street Target Price
15.33
Profit Margin
-72.47%
Operating Margin TTM
-70.02%
Return On Assets TTM
-12.0%
Return On Equity TTM
-20.44%
Revenue TTM
50.2M
Revenue Per Share TTM
1.56
Quarterly Revenue Growth YOY
23.3%
Gross Profit TTM
26.0M
EBITDA
-40.4M
Diluted Eps TTM
-1.13
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.27
EPS Estimate Next Year
-1.14
EPS Estimate Current Quarter
-0.26
EPS Estimate Next Quarter
-0.33

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for 908 Devices Inc.(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 164.77%

Current $5.79
Target $15.33

Company Financials

FY18Y/Y Change
Revenue
22.1M
-
Net Income
-7.5M
-
Net Profit Margin
-34.17%
-
FY19Y/Y Change
Revenue
18.0M
↓ 18.51%
Net Income
-15.2M
↑ 101.75%
Net Profit Margin
-84.6%
↓ 50.43%
FY20Y/Y Change
Revenue
26.9M
↑ 49.64%
Net Income
-6.9M
↓ 54.38%
Net Profit Margin
-25.79%
↑ 58.81%
FY21Y/Y Change
Revenue
42.2M
↑ 56.93%
Net Income
-22.1M
↑ 218.86%
Net Profit Margin
-52.4%
↓ 26.61%
FY22Y/Y Change
Revenue
46.9M
↑ 11.01%
Net Income
-31.7M
↑ 43.53%
Net Profit Margin
-67.75%
↓ 15.35%
FY23Y/Y Change
Revenue
50.2M
↑ 7.21%
Net Income
-36.4M
↑ 14.66%
Net Profit Margin
-72.47%
↓ 4.72%
Q3 FY22Q/Q Change
Revenue
15.8M
↑ 42.24%
Net Income
-5.4M
↓ 31.49%
Net Profit Margin
-33.96%
↑ 36.53%
Q4 FY22Q/Q Change
Revenue
11.6M
↓ 26.3%
Net Income
-9.2M
↑ 72.33%
Net Profit Margin
-79.4%
↓ 45.44%
Q1 FY23Q/Q Change
Revenue
9.5M
↓ 18.52%
Net Income
-10.9M
↑ 17.5%
Net Profit Margin
-114.49%
↓ 35.09%
Q2 FY23Q/Q Change
Revenue
12.1M
↑ 27.48%
Net Income
-9.3M
↓ 13.96%
Net Profit Margin
-77.28%
↑ 37.21%
Q3 FY23Q/Q Change
Revenue
14.3M
↑ 18.22%
Net Income
-7.1M
↓ 24.11%
Net Profit Margin
-49.61%
↑ 27.67%
Q4 FY23Q/Q Change
Revenue
14.4M
↑ 0.38%
Net Income
-7.4M
↑ 4.74%
Net Profit Margin
-51.77%
↓ 2.16%
FY18Y/Y Change
Total Assets
27.7M
-
Total Liabilities
77.9M
-
FY19Y/Y Change
Total Assets
37.7M
↑ 35.73%
Total Liabilities
100.8M
↑ 29.4%
FY20Y/Y Change
Total Assets
178.8M
↑ 374.82%
Total Liabilities
39.8M
↓ 60.54%
FY21Y/Y Change
Total Assets
260.9M
↑ 45.9%
Total Liabilities
46.3M
↑ 16.38%
FY22Y/Y Change
Total Assets
242.6M
↓ 7.02%
Total Liabilities
52.0M
↑ 12.28%
FY23Y/Y Change
Total Assets
203.0M
↓ 16.33%
Total Liabilities
37.5M
↓ 27.89%
Q3 FY22Q/Q Change
Total Assets
249.3M
↑ 0.93%
Total Liabilities
52.8M
↑ 15.04%
Q4 FY22Q/Q Change
Total Assets
242.6M
↓ 2.69%
Total Liabilities
52.0M
↓ 1.5%
Q1 FY23Q/Q Change
Total Assets
218.4M
↓ 9.97%
Total Liabilities
37.8M
↓ 27.3%
Q2 FY23Q/Q Change
Total Assets
210.8M
↓ 3.47%
Total Liabilities
36.4M
↓ 3.77%
Q3 FY23Q/Q Change
Total Assets
208.5M
↓ 1.12%
Total Liabilities
38.5M
↑ 5.98%
Q4 FY23Q/Q Change
Total Assets
203.0M
↓ 2.64%
Total Liabilities
37.5M
↓ 2.74%
FY18Y/Y Change
Operating Cash Flow
-8.9M
-
Investing Cash Flow
-1.2M
-
Financing Cash Flow
4.0M
-
FY19Y/Y Change
Operating Cash Flow
-11.0M
↑ 23.67%
Investing Cash Flow
-392.0K
↓ 66.41%
Financing Cash Flow
22.2M
↑ 456.9%
FY20Y/Y Change
Operating Cash Flow
4.1M
↓ 137.54%
Investing Cash Flow
-9.0K
↓ 97.7%
Financing Cash Flow
137.2M
↑ 516.95%
FY21Y/Y Change
Operating Cash Flow
-29.1M
↓ 803.99%
Investing Cash Flow
-737.0K
↑ 8088.89%
Financing Cash Flow
94.7M
↓ 30.95%
FY22Y/Y Change
Operating Cash Flow
-20.9M
↓ 28.03%
Investing Cash Flow
-15.8M
↑ 2044.78%
Financing Cash Flow
1.2M
↓ 98.76%
Q3 FY22Q/Q Change
Operating Cash Flow
-4.9M
↓ 52.56%
Investing Cash Flow
-14.5M
↑ 20047.22%
Financing Cash Flow
171.0K
↓ 63.38%
Q4 FY22Q/Q Change
Operating Cash Flow
-5.1M
↑ 3.6%
Investing Cash Flow
-612.0K
↓ 95.78%
Financing Cash Flow
411.0K
↑ 140.35%
Q1 FY23Q/Q Change
Operating Cash Flow
-10.6M
↑ 108.11%
Investing Cash Flow
-1.2M
↑ 93.63%
Financing Cash Flow
-15.4M
↓ 3842.34%
Q2 FY23Q/Q Change
Operating Cash Flow
-7.9M
↓ 25.97%
Investing Cash Flow
-19.9M
↑ 1582.36%
Financing Cash Flow
-401.0K
↓ 97.39%

Technicals Summary

Sell

Neutral

Buy

908 Devices Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
908 Devices Inc.
908 Devices Inc.
-9.67%
2.19%
-29.91%
-88.48%
-87.61%
Stryker Corporation
Stryker Corporation
-3.4%
29.52%
16.83%
33.17%
80.94%
Boston Scientific Corp.
Boston Scientific Corp.
2.78%
35.87%
31.56%
66.59%
80.03%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-2.2%
26.67%
7.41%
2.59%
43.13%
Abbott Laboratories
Abbott Laboratories
-5.52%
18.37%
4.39%
-11.97%
40.79%
Medtronic Plc
Medtronic Plc
-4.12%
11.68%
-2.42%
-36.33%
-7.76%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
908 Devices Inc.
908 Devices Inc.
NA
NA
NA
-1.27
-0.2
-0.12
NA
5.09
Stryker Corporation
Stryker Corporation
41.51
41.51
2.92
11.85
0.18
0.07
0.01
48.92
Boston Scientific Corp.
Boston Scientific Corp.
64.16
64.16
1.81
2.25
0.09
0.04
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
39.25
39.25
5.19
2.76
0.22
0.12
NA
11.06
Abbott Laboratories
Abbott Laboratories
33.47
33.47
5.99
4.59
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
26.14
26.14
1.56
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
908 Devices Inc.
908 Devices Inc.
Buy
$199.8M
-87.61%
NA
-72.47%
Stryker Corporation
Stryker Corporation
Buy
$130.1B
80.94%
41.51
15.44%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$100.9B
80.03%
64.16
11.18%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$54.3B
43.13%
39.25
23.36%
Abbott Laboratories
Abbott Laboratories
Buy
$189.3B
40.79%
33.47
14.27%
Medtronic Plc
Medtronic Plc
Buy
$109.3B
-7.76%
26.14
13.0%

Institutional Holdings

  • ARK Investment Management LLC

    13.21%

  • Granahan Investment Management Inc..

    6.19%

  • Ameriprise Financial Inc

    5.74%

  • BlackRock Inc

    5.43%

  • Vanguard Group Inc

    5.30%

  • Eventide Asset Management, LLC

    4.35%

Corporate Announcements

  • 908 Devices Inc. Earnings

    908 Devices Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

908 devices, is democratizing chemical analysis by way of mass spectrometry, offering point-of-need chemical analysis devices ranging from rugged, handheld chemical detection tools to compact, tiny footprint analyzers and fast separation devices. these purpose-built and user-centric devices serve a range of industries including safety and security, oil & gas, life sciences and other applied markets. 908 devices is headquartered in the heart of boston where they research, design and manufacture innovative products based on high pressure mass spectrometry (hpms).

Organization
908 Devices Inc.
Employees
230
CEO
Dr. Kevin J. Knopp Ph.D.
Industry
Healthcare

Discover More

FAQs